AR041303A1 - Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4" - Google Patents

Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4"

Info

Publication number
AR041303A1
AR041303A1 ARP030103390A ARP030103390A AR041303A1 AR 041303 A1 AR041303 A1 AR 041303A1 AR P030103390 A ARP030103390 A AR P030103390A AR P030103390 A ARP030103390 A AR P030103390A AR 041303 A1 AR041303 A1 AR 041303A1
Authority
AR
Argentina
Prior art keywords
groups
group
substituted
compound
alkyl group
Prior art date
Application number
ARP030103390A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32030864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR041303(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AR041303A1 publication Critical patent/AR041303A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Estos compuestos tienen actividad de unión al receptor 5-HT4, y por lo tanto son útiles para tratar la enfermedad de reflujo gastroesofágico, dispepsia no ulcerosa, dispepsia funcional, síndrome del intestino irritable o similares, en un mamífero,especialmente seres humanos. La presente también proporciona una composición farmacéutica que comprende el compuesto precedente. Reivindicación 1: Un compuesto de fórmula (1), caracterizado porque: R1 representa un átomo de hidrógeno o un átomo dehalógeno; R2 representa un átomo de hidrógeno, un grupo alquilo C1-6, un grupo aminocarbonilo, o grupo mono o dialquilaminocarbonilo C1-6; R3 representa un grupo alquilo C1-10; dicho grupo alquilo en R3 está sustituido con al menos un sustituyenteseleccionado del grupo que consta de sustituyentes a, definidos a continuación; dichos sustituyentes a se seleccionan del grupo que consta de grupos arilo definidos a continuación, grupos hidroxi, grupos oxo, grupos aminocarbonilo, o grupos mono odi-alquilaminocarbonilo C1-6, grupos alquilsulfonilamino C1-6, grupos heterociclo definidos a continuación, grupos heterociclocarbonilo y un grupo cicloalquilo C3-8: dichos grupos arilo C6-10; dichos grupos arilo no están sustituidos o estánsustituidos con al menos un grupo alquilo C1-6; dichos grupos heterociclo y resto heterociclo en dichos grupos heterociclocarbonilo son grupos cíclicos de 5 a 10 miembros que contiene 1 a 4 heteroátomos seleccionados del grupo que consta de átomosde azufre, átomos de oxígeno y átomos de nitrógeno; o una amida farmacéuticamente aceptable de dicho compuesto, o un éster farmacéuticamente aceptable de dicho compuesto, y sus sales farmacéuticamente aceptables.
ARP030103390A 2002-09-20 2003-09-18 Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4" AR041303A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41242602P 2002-09-20 2002-09-20

Publications (1)

Publication Number Publication Date
AR041303A1 true AR041303A1 (es) 2005-05-11

Family

ID=32030864

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030103390A AR041303A1 (es) 2002-09-20 2003-09-18 Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4"

Country Status (13)

Country Link
US (1) US6951867B2 (es)
EP (1) EP1543004A1 (es)
JP (1) JP2006502180A (es)
AR (1) AR041303A1 (es)
AU (1) AU2003259482A1 (es)
BR (1) BR0314584A (es)
CA (1) CA2499494A1 (es)
GT (1) GT200300208A (es)
MX (1) MXPA05003065A (es)
PA (1) PA8582901A1 (es)
TW (1) TW200406412A (es)
UY (1) UY27992A1 (es)
WO (1) WO2004026868A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523077A1 (en) * 2003-04-21 2004-11-04 Pfizer Inc. Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
JP4704353B2 (ja) * 2003-11-24 2011-06-15 ファイザー株式会社 ５−ｈｔ４受容体アゴニスト活性を有するキノリンカルボン酸化合物
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EA200801608A1 (ru) * 2004-06-15 2008-10-30 Пфайзер Инк. Производные бензимидазолонкарбоновой кислоты
ATE441646T1 (de) 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
WO2006052889A2 (en) 2004-11-05 2006-05-18 Theravance, Inc. Quinolinone-carboxamide compounds
MX2007007818A (es) 2004-12-22 2007-09-11 Theravance Inc Compuestos de indazol-carboxamida.
EA013567B1 (ru) 2005-03-02 2010-06-30 Тереванс, Инк. Хинолиноновые соединения в качестве агонистов рецептора 5-ht
MY147756A (en) 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
GB0603550D0 (en) * 2006-02-22 2006-04-05 Glaxo Group Ltd Novel compounds
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP5393677B2 (ja) * 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
WO2010091411A1 (en) * 2009-02-09 2010-08-12 Glaxosmithkline Llc Piperidinyl cyclic amido antiviral agents
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
JP5836280B2 (ja) 2009-11-06 2015-12-24 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
CA2779442A1 (en) 2009-11-06 2011-05-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
KR101737388B1 (ko) * 2010-02-12 2017-05-18 에스크엣 인크. 치매 치료용 ５－ｈｔ４ 수용체 작용제
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
AU2015342887B2 (en) 2014-11-06 2020-09-10 Bial - R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
CN109311887B (zh) 2016-04-06 2022-09-13 Bial研发投资股份有限公司 吡唑并[1,5-a]嘧啶基甲酰胺化合物以及它们在治疗医学病症中的用途
CA3020310A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3452455A4 (en) * 2016-05-05 2019-11-13 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
CN109311902B (zh) 2016-05-05 2022-07-15 Bial研发投资股份有限公司 取代的咪唑并[1,2-b]哒嗪、咪唑并[1,5-b]哒嗪、相关化合物及其用途
GB2589573A (en) 2019-12-02 2021-06-09 Caterpillar Inc Bucket actuator assembly with resilient bump stop

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
JP2643274B2 (ja) 1988-04-08 1997-08-20 三菱化学株式会社 イミダゾ〔１，２−ａ〕ピリジン誘導体
FR2646894B3 (fr) * 1989-05-11 1991-07-12 Sleever Int Procede pour controler la temperature dans un four-tunnel ouvert a ses deux extremites, et dispositif pour la mise en oeuvre du procede
US5196547A (en) 1991-03-07 1993-03-23 G. D. Searle & Co. Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5260303A (en) 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5219850A (en) 1991-03-07 1993-06-15 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5137893A (en) 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
GB9221468D0 (en) * 1992-10-13 1992-11-25 Smithkline Beecham Plc Pharmaceuticals
AU3192295A (en) 1994-08-11 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition containing the same
EP0944387A1 (en) 1996-01-30 1999-09-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU715202B2 (en) 1996-04-03 2000-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2002509918A (ja) 1998-03-31 2002-04-02 アケイディア ファーマスーティカルズ インコーポレイテッド ムスカリン性レセプタに活性を有する化合物
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
JP4032566B2 (ja) 1999-06-21 2008-01-16 東レ株式会社 発光素子
US6624162B2 (en) * 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators
ES2248616T3 (es) * 2001-10-22 2006-03-16 Pfizer Inc. Compuestos imidazopiridina como moduladores del receptor 5-ht4.

Also Published As

Publication number Publication date
PA8582901A1 (es) 2004-05-26
EP1543004A1 (en) 2005-06-22
US20040127514A1 (en) 2004-07-01
JP2006502180A (ja) 2006-01-19
CA2499494A1 (en) 2004-04-01
WO2004026868A1 (en) 2004-04-01
US6951867B2 (en) 2005-10-04
UY27992A1 (es) 2004-04-30
AU2003259482A1 (en) 2004-04-08
BR0314584A (pt) 2005-08-09
TW200406412A (en) 2004-05-01
MXPA05003065A (es) 2005-05-27
GT200300208A (es) 2004-05-20

Similar Documents

Publication Publication Date Title
AR041303A1 (es) Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5-ht4"
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR055878A1 (es) Derivados de ciclopropanocarboxamida
PE20230820A1 (es) Derivados de biarilo como inhibidores de la interaccion proteina-proteina de yap/taz-tead
EA200800476A1 (ru) Макроциклические ингибиторы вируса гепатита с
NO20072116L (no) Farmasoytiske forbindelser
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
DE602005005167D1 (de) 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
CO6331462A2 (es) Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
AR057106A2 (es) USO DE COMPUESTOS DERIVADOS DE PIPERAZINA UTILES COMO ANTAGONISTAS CCR5, PARA LA PREPARACIoN DE MEDICAMENTOS
ECSP045359A (es) Isoxazolinas 5 metiloximetil sustituidas por 3-heteroarilo utilizadas con herbicidas
AR038235A1 (es) Compuestos de espiropiperidina n-sustituidos como ligandos para el receptor orl-1
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
AR056762A1 (es) (4 -(6-halo-7- substituidos -2,4- dioxo-1,4- dihidro-2h-quinazolin-3-il- fenil)-5- cloro- tiophen-2- il sulfonilureas y formas y metodos
AR031809A1 (es) Quinolonas antimicrobianas, sus composiciones y usos
AR037534A1 (es) Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios
AR035069A1 (es) Compuestos inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas, composicion farmaceutica, procedimiento de tratamiento
AR082696A1 (es) Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras

Legal Events

Date Code Title Description
FB Suspension of granting procedure